450 results about "Melanoma" patented technology

The invention provides a coordination nano assembly of chiral cyclopeptide and manganese ions as well as a preparation method and application of the coordination nano assembly. According to the method, a manganese superoxide dismutase protein structural domain and a unique tumor microenvironment of melanoma high tyrosinase are combined, and polypeptide sequences L-YD-hL-DD-h, L-YL-HL-DL-H and D-yD-hD-dD-h with different chirality are designed for the first time; the chirality of the polypeptide is regulated and controlled, the in-vivo circulation stability and the cell entry efficiency of the nano assembly are improved, the coordination self-assembly of manganese and different chiral cyclopeptides is realized, and the in-situ oxidation of an in-vivo tumor microenvironment is simulated for photo-thermal therapy and cell membrane coating. The method disclosed by the invention is simple, mild in experimental condition and easy to operate, the prepared cell membrane coated nano assembly not only has long circulation stability and high cell entry efficiency, but also can realize mild photo-thermal therapy through in-situ oxidation, releases manganese ions to activate a CGAS-STING pathway for immunotherapy of tumors, and has a wide application prospect. The potential application value is realized in the field of combined treatment of tumors.

The invention discloses an application of a polysaccharide monomer separated from schisandra chinensis in preparation of a PD-L1 + TAMs activator. A large number of experiments show that the polysaccharide monomer schisanan B separated from schisandra chinensis can effectively activate PD-L1 + TAMs cell subsets, so that the phagocytosis of TAMs is enhanced, and the proliferation of tumor cells is inhibited; therefore, it is determined that the polysaccharide monomer schisanan B separated from schisandra chinensis can serve as a natural PD-L1 + TAMs cell subset activator to be used for treating cancers such as non-small cell lung cancer, intestinal cancer, melanoma, urothelial carcinoma or liver cancer, and the polysaccharide monomer schisanan B has the advantages of being free of toxic and side effects, low in price, wide in adaptive patient population and the like.

The invention provides a microneedle preparation for co-delivering photo-thermal nano-enzyme and elemene as well as a preparation method and application of the microneedle preparation. The preparation method comprises the following steps: firstly, preparing a novel photo-thermal nano enzyme Au (at) MoS2 through a two-step water phase synthesis strategy; benefited from the synergistic effect of the hybrid material, the nano-enzyme shows significantly enhanced near-infrared (NIR) photothermal effect, peroxidase-like (POD) activity and glutathione-like peroxidase (GSHOx) activity, and can effectively remodel the tumor microenvironment and destroy the redox steady state. Furthermore, photo-thermal nano enzyme, beta-ELE and hyaluronic acid are used as raw materials, and a novel soluble microneedle preparation is successfully prepared through a template method. The novel composite microneedle is in a sharp rectangular pyramid shape, growth of melanoma can be effectively inhibited through percutaneous delivery of photo-thermal nano-enzyme and beta-ELE, remarkable systemic toxicity is avoided, and an innovative strategy is provided for non-invasive, efficient and safe melanoma combined treatment.

The present invention relates to a hetero (aromatic) ring-substituted cyclic diamine compound, the preparation thereof and the use thereof in the preparation of a drug for treating and / or preventing tumors. The structural formula of the compound is as shown in (I). The compound has a significant inhibitory effect on the growth of cells of tumors such as leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophageal cancer, glioma, kidney cancer, nasopharyngeal carcinoma, liver cancer, gastric cancer and pancreatic cancer. Compared with the prior art, the compound of the present invention has a broad-spectrum anti-tumor activity, has a good effect on inhibiting tumors, and has an effect of degrading PD-L1 proteins, and is thus a PD-L1 immunomodulator.

The invention discloses an application of the number of neutrophils in predicting the curative effect of oncolytic viruses in treating tumors. In the application, the neutrophile granulocyte number level in the blood of a tumor patient is closely associated with the tumor treatment effect, and the applicable tumor syndromes are common, including melanoma, colorectal cancer, esophageal cancer, head and neck tumors, gastric cancer, biliary tract system tumors, sarcoma and other tumors. In the application, the critical value of the number of neutrophils for predicting the tumor treatment effect is 2 * 10 < 9 >-5.5 * 10 < 9 > / L, and the most preferable critical value is 4.0 * 10 < 9 > / L; the curative effect of OH2 single-drug treatment on tumor patients with the neutrophil number level below a critical value is better than that of tumor patients with the neutrophil number level above the critical value.

The invention provides a preparation method of collagen and an application of the collagen in anti-aging. According to the invention, the anti-aging antioxidant collagen peptide F-5-B is obtained through enzymolysis and column separation identification. It is identified that the polypeptide has good DPPH free radical scavenging capacity, ABTS free radical scavenging capacity and lipid peroxidation reaction inhibiting capacity, the collagen peptide F-5-B can further inhibit melanoma cells from synthesizing melanin, and the polypeptide can further obviously increase the SOD level in the liver of a mouse. SOD can help the body resist attack of free radicals, so that the aging process is slowed down. Therefore, the anti-aging pharmaceutical composition prepared from the polypeptide has a relatively good application prospect.

The invention discloses nano-engineered microalgae for photoimmunotherapy of melanoma and a preparation method of the nano-engineered microalgae. The preparation method comprises the following steps: S1, respectively putting tannic acid, potassium carbonate, sodium citrate and HAuCl4. 3H2O into water to prepare a tannic acid solution with the concentration of 4.3 mg / mL, a potassium carbonate solution with the concentration of 20.7 mg / mL, a sodium citrate reduction solution with the concentration of 0.7 mg / mL and a HAuCl4 solution with the concentration of 10.0 mg / mL; s2, dissolving a tannic acid solution and a potassium carbonate solution in the sodium citrate reduction solution to obtain a mixed solution; s3, the mixed solution is heated under stirring, a HAuCl4 solution is dropwise added, stirring continues, and AuNP is obtained; and S4, mixing the AuNP obtained in the step S3 with the microalgae PCC 7942, standing, incubating, and centrifugally washing, so as to obtain the nano-engineered microalgae PCC-coated AuNP. The functionalized microalgae drug delivery system (PCC-coated AuNP) prepared by the invention has the performance of respectively generating O2 and H2 through photosynthesis and photocatalytic reaction under the irradiation of 635 nm red light.

Disclosed in the present disclosure are an inhibitor against CTGF RNA, MITF RNA and SRD5A2 RNA and the use of the inhibitor. The inhibitor is a gene editing system. The gene editing system of the present disclosure is capable of knocking down CTGF RNA, MITF RNA and SRD5A2 RNA, and can be used for repairing scars, whitening skin, reducing or eliminating chloasma, preventing or treating melanoma, and / or preventing or treating androgenetic alopecia.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a 3-sulfamoyl benzamide compound as well as a preparation method and application thereof. The 3-sulfamoyl benzamide compound has a structure as shown in a formula I. In the formula I, X is chlorine or trifluoromethyl; r1 and R2 are independently C1-4 alkyl or R1, R2 and N atoms connected with R1 and R2 jointly form a heterocyclic group, and the heterocyclic group is a substituted or unsubstituted five-membered or six-membered heterocyclic group; and when the heterocyclic group is a substituted heterocyclic group, the substituent group in the substituted heterocyclic group is one or more of C1-4 alkyl, phenyl and acetyl. The 3-sulfamoyl benzamide compound disclosed by the invention has a remarkable proliferation inhibition effect on HCT116 colon cancer cells, HeLa human cervical cancer cells, MDA-MB-231 human breast cancer cells and A375 human malignant melanoma cells.

The invention belongs to the field of biological pharmacy, and provides keratin YK93-4, a coding nucleic acid molecule thereof, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method and a pharmaceutical composition of the keratin YK93-4. The invention also provides application of the keratin YK93-4 and related products thereof in preparation of medicines for treating lung cancer, lymphoma, breast cancer, melanoma, hysteromyoma, benign prostatic hyperplasia and the like.

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly ovarian cancer, osteosarcoma, colon cancer, breast cancer, skin cancer, melanoma, esophageal cancer, esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESSC), particularly esophageal cancer, or EAC or ESSC.

The embodiment of the invention provides a melanoma postoperative wound intelligent dressing, and belongs to the technical field of intelligent medical treatment. The intelligent dressing for the wound after the melanoma operation comprises a multiple monitoring module, an intelligent processing module and an on-demand drug delivery module which are arranged on a dressing base body, the multiple monitoring module is used for acquiring biological signals of a wound surface microenvironment in real time; and the intelligent processing unit analyzes the biological signal to generate a wound state judgment result, and controls the on-demand drug delivery module to trigger electrical stimulation or thermal stimulation based on the wound state judgment result so as to realize on-demand drug release. According to the scheme, the deep learning intelligent early warning model fusing the generative adversarial network and the Transform structure is constructed, high-precision analysis and dynamic risk judgment of melanoma postoperative wound multi-dimensional time sequence data are achieved, and the accuracy and stability of wound state recognition are effectively improved.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-6, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-6 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, analgesia, lactation, breast cancer, lung cancer, uterine fibroids, coagulation, etc.

The invention belongs to the field of biological pharmacy, and provides keratin YK93-5, a coding nucleic acid molecule thereof, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method and a pharmaceutical composition of the keratin YK93-5. The invention also provides application of the keratin YK93-5 and other products in preparation of drugs for treating lung cancer, lymphoma, breast cancer, melanoma, hysteromyoma, prostatic hyperplasia and the like.

The invention discloses an ultrasonic controllable multifunctional microneedle patch as well as a preparation method and application thereof, and belongs to the technical field of biological materials. The preparation method comprises the following steps: preparing crystalline CoW-LDH nanosheets from Co (NO3) 2.6 H2O, Na2WO4. 2H2O and NaOH, dispersing the crystalline CoW-LDH nanosheets in PBS (Phosphate Buffer Solution), centrifuging and collecting the crystalline CoW-LDH nanosheets, and re-dispersing the crystalline CoW-LDH nanosheets in ultrapure water to obtain amorphous CoW-LDH nanosheets; adding PEG (Polyethylene Glycol), ultrasonically dispersing, stirring at room temperature, centrifuging, collecting and centrifugally washing with ultrapure water to obtain a PEG modified amorphous CoW-LDH nanosheet; and adding microalgae and an amorphous CoW-LDH nanosheet modified by PEG (Polyethylene Glycol) to prepare the ultrasonic controllable multifunctional microneedle patch. The multifunctional microneedle patch disclosed by the invention is high in biological safety, can realize ultrasonic controllability, has a sonodynamic treatment effect and an oxygen supply effect, remarkably inhibits melanoma recurrence and remarkably promotes wound healing, and has a wide application prospect.

The invention relates to a DDPM-based melanoma intelligent segmentation method and system. The method comprises the following steps of obtaining a dermatoscope image of melanoma and performing image preprocessing; inputting the dermatoscope image of the melanoma after image preprocessing into a DDPM segmentation model, gradually adding noise through a forward denoising process, gradually removing noise through a backward denoising process, further learning probability distribution of the dermatoscope image of the melanoma, and obtaining a segmentation result of the melanoma; the DDPM segmentation model comprises an encoder and a decoder, the encoder comprises a multi-scale feature fusion module and a double-attention module, and the encoder extracts multi-scale features of a dermatoscope image of the melanoma through a multi-scale convolutional layer; and the decoder gradually recovers the segmentation result of the dermatoscope image of the melanoma according to the multi-scale features of the dermatoscope image of the melanoma through up-sampling and feature fusion operations. Compared with the prior art, the method has the advantage that accurate segmentation of the melanoma image is realized.

The invention provides a docetaxel-loaded platelet delivery system as well as a preparation method and application thereof, and relates to the technical field of medicines. According to the invention, the docetaxel-loaded platelet delivery system is obtained by loading the docetaxel with the platelets for the first time, so that the problem that in the prior art, the traditional docetaxel preparation (injection) needs to be solubilized by polysorbate 80, so that allergy is easily caused is avoided, the safety and biocompatibility of the docetaxel medicine are improved, and the docetaxel-loaded platelet delivery system is suitable for clinical application. And the docetaxel-loaded platelet delivery system has excellent stability and can be stored at normal temperature for a long time. The invention provides the preparation method of the docetaxel-loaded platelet delivery system, and the method is simple to operate, high in encapsulation efficiency and drug loading rate and suitable for popularization. The docetaxel-loaded platelet delivery system disclosed by the invention has an outstanding treatment effect on melanoma and has a good application prospect.

The invention relates to a hetero (aromatic) ring substituted cyclic diamine compound, preparation thereof and application of the hetero (aromatic) ring substituted cyclic diamine compound in preparation of drugs for treating and / or preventing tumors. The structural formula of the compound is shown as (I). The compound has an obvious growth inhibition effect on tumor cells of leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophagus cancer, glioma, kidney cancer, nasopharynx cancer, liver cancer, stomach cancer, pancreatic cancer and the like. The compound disclosed by the invention has broad-spectrum anti-tumor activity; the compound has a good tumor inhibition effect and a PD-L1 protein degradation effect, and is a PD-L1 immunomodulator.

Chimeric antigen receptors for use in treating malignant melanoma and other cancers expressing CS1 are described.

The invention discloses an application of neomycin in preparation of a medicine for treating tumors, and experiments show that tumor growth can be significantly inhibited by inhibiting interference of LPS (Lipopolysaccharide) on an STING pathway. The invention further provides a pharmaceutical composition containing the neomycin and the STING agonist (such as diABZI, cGAMP or CMA), the neomycin and the STING agonist show a synergistic effect in tumor resistance, the composition can be used for preparing drugs for treating tumors such as melanoma and colon cancer, and it is indicated that the neomycin or the combination of the neomycin and the STING agonist has wide application prospects in the medical field.

The invention belongs to the technical field of biology, and particularly relates to a medicine for treating solid tumors and application thereof. The medicine provided by the invention simultaneously comprises F1, F3 and 5-FU, and every 100 mu L of the medicine comprises 20 to 40 mu g of F1, 20 to 40 mu g of F3 and 100 to 900 mu g of 5-FU. Experiments prove that in vitro, after the F1 / F3 and the 5-FU are combined for medication, the F1 / F3 and the 5-FU cannot synergistically generate an inhibition effect on tumor cells; however, in vivo, the combination of F1 / F3 and 5-FU can effectively inhibit the growth of solid tumor cells, such as colorectal cancer, melanoma and cervical cancer, and the combined use effect is obviously higher than that of single use of F1 / F3 or 5-FU. Therefore, the invention discloses that F1 / F3 and 5-FU are combined to synergistically inhibit the proliferation of the solid tumor cells for the first time, provides a novel medicine for the treatment of solid tumors, and has important significance.

The invention discloses a fluorescent / photoacoustic dual-mode diagnosis and treatment probe for detection and photodynamic removal of senescent cells, a preparation method and application, the probe takes a sulfur-substituted hemicyanine dye as a parent structure, a novel bromo-glycoside ligand is covalently coupled, and a blue-green solid is obtained after gradient purification. The probe system shows a remarkable optical response characteristic on beta-galactosidase (beta-Gal) and ideal singlet oxygen (1O2) generation efficiency; an optical signal and a photodynamic therapy effect of the probe can be specifically activated by beta-galactosidase (beta-Gal) overexpressed in cancerous cells and senescent cells under a light excitation condition; the result is successfully verified in a palbociclib-induced senescence melanoma model. According to the probe disclosed by the invention, collaborative regulation and control of dual-mode visual monitoring and precise photodynamic therapy of beta-Gal enzyme activity are realized for the first time, a novel tool is provided for researching a molecular mechanism of cell aging and developing a diagnosis and treatment strategy of aging-related diseases, and the probe has a remarkable application value in the fields of anti-tumor treatment and degenerative diseases.

The invention relates to the field of antitumor drugs, in particular to a thiophene acetyl tetrahydro-beta-carboline compound and application thereof. The thiophene acetyl tetrahydro-beta-carboline compound or the pharmaceutically acceptable salt thereof, and the pharmaceutical composition containing the compound can be used for preparing medicines for preventing and / or treating various cancers. The cancer is at least one of breast cancer, lung cancer, osteosarcoma, melanoma, gastric cancer, pancreatic cancer, kidney cancer, glioma and ovarian cancer. Activity screening is carried out on various compounds, it is found for the first time that the 12 compounds provided by the invention have remarkable broad-spectrum inhibitory activity on various human cancer cell lines, and key candidate compounds are provided for developing novel anti-cancer drugs.

The present disclosure features methods for identifying pateints having a hyperproliferative disease, disorder, or condition responsive to phosphodiesterase 3 (PDE3) and schlafen family member 12 (SLFN12) complex formation. The hyperproliferative disease, disorder, or condition may be cancer in a patient including glioblastoma, melanoma, ovarian cancer, cervical cancer, sarcoma, or hematopoietic cancers, such as acute myeloid leukemia. Those responsive diseases, disorders, or conditions may be identified using the biomarker AIP and / or TRRAP in combination with those biomarkers pertinent to phosphodieseterase 3 and schlafen family member 12 complexes which may be formed by PDE3 modulation with certain active compounds. Expression of combinations of these biomarkers have been shown to correlate with active compound (e.g., PDE3 modulator, PDE3A modulator, PDE3B modulator) sensitivity.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-8, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-8 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, breast cancer, lung cancer, analgesia, lactation, uterine fibroids, coagulation, etc.

The invention relates to the field of natural medicinal chemistry, in particular to application of mirabilis himalaica to preparation of a product with whitening and anti-oxidation effects, and innovatively adopts mirabilis himalaica to research the whitening and anti-oxidation effects. The mirabilis himalaica-derived extracellular vesicle-like nanoparticles are found to be capable of reducing the content of melanin in melanoma cells at the cellular level and inhibiting the activity of tyrosinase. In addition, the mirabilis himalaica source extracellular vesicle-like nanoparticles can also scavenge free radical ions, inhibit the generation of active oxygen in cells and promote the improvement of cell viability. The mirabilis himalaica-derived extracellular vesicle-like nanoparticles disclosed by the invention can be sufficiently internalized and absorbed by melanoma cells, the melanin content in the melanoma cells is remarkably reduced, melanin pigmentation on the epidermis of a mouse is remarkably reduced, and the mirabilis himalaica-derived extracellular vesicle-like nanoparticles also have excellent oxidation resistance. The method has potential for preparing products with whitening and antioxidant effects.

The invention discloses a design method and application of a tyrosinase (TYR) responsive drug for targeted therapy of melanoma, and belongs to the technical field of biological medicines. Based on the biological mechanism that TYR catalyzes tyrosine oxidation, a self-degradation connecting arm drug release strategy is combined, a similar 3-hydroxybenzyl alcohol structure is introduced to simulate a tyrosine substrate, specific recognition and activation of TYR on the drugs are achieved, and the problems that traditional chemotherapeutic drugs are poor in targeting property and serious in adverse reaction are hopefully solved.

The invention discloses application of Bombyx mori neuropeptide BommoOKAtype4 in preparation of a medicine for inhibiting melanoma cell growth, and belongs to the technical field of medical biology. Aiming at the technical problems that melanoma is high in malignancy degree, easy to transfer and limited in treatment means, and whether the bombyx mori neuropeptide BommoOKAtype4 can directly inhibit the growth of melanoma cells is not clear yet when the bombyx mori neuropeptide BommoOKAtype4 is mainly used for skin whitening before, the invention provides the application of the bombyx mori neuropeptide in preparing the medicine for inhibiting the melanoma cells. According to the silkworm neuropeptide, gene expression and protein functions of melanin synthesis key enzymes TYR, TRP1 and TRP2 are comprehensively inhibited by down-regulating expression of a core transcription factor MITF, so that melanoma cell proliferation is directly inhibited while melanin synthesis is inhibited, and therefore, the silkworm neuropeptide can be used for preparing drugs for treating melanoma and has a wide application prospect. A novel peptide candidate substance is provided for treatment of melanoma.

The application belongs to the technical field of biological medicine, and provides application of an NTSR1 inhibitor in preparation of a drug for enhancing the anti-tumor effect of a PD-1 monoclonal antibody, which is combined application of the NTSR1 inhibitor SR48692 and the PD-1 monoclonal antibody in preparation of a drug for treating lung cancer. The application establishes a subcutaneous lung cancer mouse model and a subcutaneous melanoma mouse model, and evaluates the growth inhibition effect of SR48692 on the two kinds of tumor cancer cells; the result shows that the NTSR1 inhibitor SR48692 can achieve the purpose of treating lung cancer and melanoma by inhibiting the growth of cancer cells.

Strategies for blocking anti-apoptotic proteins or activating proapoptotic proteins in combination with immune checkpoint blockade therapy to prevent or reverse acquired resistance are described, providing methods to detect, prevent, and / or reverse acquired resistance to ICB therapy. Anti-melanoma therapy can be enhanced by administering an effective amount of an activator of a pro-apoptotic protein, such as a BAX activator, and / or a downregulator of an anti-apoptotic protein, such as a BH3 mimetic. Also described is a method of detecting acquired resistance to anti-melanoma therapy by assaying a sample of tumor DNA for deletion and / or amplification of genes indicative of acquired resistance.